Humanigen and Chime Biologics Enter Into Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen and Chime Biologics today announced that they have entered into a manufacturing services agreement.

Click to view original post